Titan sees Braeburn as best partner to secure future of Probuphine
This article was originally published in Scrip
Titan Pharmaceuticals insists that multiple potential partners were interested in commercializing Probuphine (buprenorphine) in the US and Canada, but the company's executives said they signed a license deal with the startup firm Braeburn Pharmaceuticals to reduce the risk that the opioid addiction therapy delivered by a novel subdermal implant would be de-prioritized by a Big Pharma player.
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.